Submitted for Publication: March 24, 2011; final revision received September 30, 2011; accepted October 10, 2011.
Published Online: December 5, 2011. doi:10.1001/archgenpsychiatry.2011.160
Author Contributions: Dr Kessler had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors had full access to all of the data in the study.
Financial Disclosure: Dr Kessler has been a consultant for AstraZeneca, Analysis Group, Bristol-Myers Squibb, Cerner-Galt Associates, Eli Lilly and Co, GlaxoSmithKline, HealthCore Inc, Health Dialog, Integrated Benefits Institute, John Snow Inc, Kaiser Permanente, Matria Inc, Mensante, Merck and Co Inc, Ortho-McNeil Janssen Scientific Affairs, Pfizer Inc, Primary Care Network, Research Triangle Institute, sanofi-aventis, Shire US Inc, SRA International Inc, Takeda Global Research and Development, Transcept Pharmaceuticals Inc, and Wyeth-Ayerst; has served on advisory boards for Appliance Computing II, Eli Lilly and Co, Mindsite, Ortho-McNeil Janssen Scientific Affairs, and Wyeth-Ayerst; and has had research support for his epidemiological studies from Analysis Group, Bristol-Myers Squibb, Eli Lilly and Co, EPI-Q, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil Janssen Scientific Affairs, Pfizer Inc, sanofi-aventis, and Shire US Inc.
Funding/Support: The NCS-A is supported by grants U01-MH60220, R01-MH66627, and U01MH060220-09S1 from the National Institute of Mental Health, with supplemental support from the National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration, grant 044780 from the Robert Wood Johnson Foundation, and the John W. Alden Trust. The work of Ms He and Dr Merikangas is supported by the Intramural Research Program of the National Institute of Mental Health. The World Mental Health Data Coordination Centres have been supported by grants R01-MH070884, R13-MH066849, R01-MH069864, and R01-MH077883 from the National Institute of Mental Health, grant R01-DA016558 from the National Institute on Drug Abuse, grant FIRCA R03-TW006481 from the Fogarty International Center of the National Institutes of Health, the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the Pan American Health Organization, and unrestricted educational grants from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Ortho-McNeil, Pfizer, sanofi-aventis, and Wyeth.
Role of the Sponsors: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Disclaimer: The views and opinions expressed in this article are those of the authors and should not be construed to represent the views of any of the sponsoring organizations, agencies, or US government.
Additional Information: A complete list of NCS-A publications can be found at http://www.hcp.med.harvard.edu/ncs. A public-use version of the NCS-A data set is available for secondary analysis. Instructions for accessing the data set can be found at http://www.hcp.med.harvard.edu/ncs/index.php. A detailed set of subsample prevalence tables has been posted on the NCS Web site (http://www.hcp.med.harvard.edu/ncs/publications.php) in conjunction with the publication of this article. The NCS-A is carried out in conjunction with the World Health Organization World Mental Health Survey Initiative. A complete list of World Mental Health Survey Initiative publications can be found at http://www.hcp.med.harvard.edu/wmh/.
Additional Contributions: We thank the staff of the World Mental Health Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis.